Roche Holding (SWX:ROG) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ROG 주식 개요

Roche Holding AG는 유럽, 북미, 라틴 아메리카, 아시아, 아프리카, 호주 및 오세아니아에서 제약 및 진단 사업을 영위하고 있습니다.

ROG 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	3/6
과거 실적	4/6
재무 상태	4/6
배당금	5/6

보상

공정 가치 추정치보다 낮은 63.2% 에서 거래

수익은 매년 8.54% 증가할 것으로 예상됩니다.

3.84% 의 안정적인 배당금을 지급합니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

부채비율이 높네요

Roche Holding AG 경쟁사

Novartis

SWX:NOVN

CHF191.8b

Dottikon ES Holding

SWX:DESN

CHF3.6b

AstraZeneca

LSE:AZN

UK£193.3b

Johnson & Johnson

NYSE:JNJ

US$358.0b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Roche Holding
과거 주가
현재 주가	CHF252.80
52주 최고치	CHF277.90
52주 최저치	CHF212.90
베타	0.16
11개월 변경	9.72%
3개월 변경 사항	12.11%
1년 변경 사항	-8.57%
33년 변화	-26.68%
5년 변화	-7.96%
IPO 이후 변화	868.58%

최근 뉴스 및 업데이트

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

주주 수익률

	ROG	CH Pharmaceuticals	CH 마켓
7D	2.1%	0.6%	-0.09%
1Y	-8.6%	19.9%	4.0%

수익률 대 산업: ROG 지난 1년 동안 19.4 %를 반환한 Swiss Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ROG 지난 1년 동안 4.6 %를 반환한 Swiss 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	2.7%
Pharmaceuticals Industry Average Movement	3.7%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	6.0%
10% least volatile stocks in CH Market	1.9%

안정적인 주가: ROG 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ROG 의 주간 변동성( 3% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG는 유럽, 북미, 라틴 아메리카, 아시아, 아프리카, 호주 및 오세아니아에서 제약 및 진단 사업을 영위하고 있습니다. 빈혈, 혈액 및 고형 종양, 피부과, 혈우병, 염증 및 자가 면역, 신경계 질환, 안과, 호흡기 질환, 이식 등의 치료 분야에서 의약품을 공급하고 있습니다. 또한 다양한 치료 분야를 위한 제품을 개발하고 있습니다.

Roche Holding AG 기본 사항 요약

Roche Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ROG 기본 통계
시가총액	CHF203.98b
수익(TTM)	CHF11.50b
수익(TTM)	CHF60.44b

17.5x

P/E 비율

3.3x

P/S 비율

ROG 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ROG 손익 계산서(TTM)
수익	CHF60.44b
수익 비용	CHF15.60b
총 이익	CHF44.84b
기타 비용	CHF33.35b
수익	CHF11.50b

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	14.42
총 마진	74.19%
순이익 마진	19.02%
부채/자본 비율	88.0%

ROG 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

3.8%

현재 배당 수익률

67%

지급 비율

ROG 주식 개요

보상

위험 분석

Roche Holding AG 경쟁사

SWX:NOVN

CHF191.8b

SWX:DESN

CHF3.6b

LSE:AZN

UK£193.3b

NYSE:JNJ

US$358.0b

가격 내역 및 성능

최근 뉴스 및 업데이트

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Recent updates

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making